MedGene Therapeutics

MedGene Therapeutics is a private U.S. cell therapy biotech developing autologous T-cell immunotherapies for solid tumors. The company centers its approach on two proprietary or exclusively licensed platforms: PBL-T, which isolates tumor-reactive lymphocytes from peripheral blood rather than tumor tissue, and RIV-8, a technology intended to counter T-cell exhaustion and enhance anti-tumor activity. MedGene has described initial focus areas including metastatic soft tissue sarcoma and metastatic follicular thyroid cancer, based in part on NIH-patented technology under an exclusive commercialization license. The company appears to remain in the preclinical stage and is positioning its technology as a next-generation adoptive cell therapy approach for hard-to-treat solid tumors.